Cutaneous squamous cell carcinoma (CSCC) is a highly prevalent malignancy with rising incidence, particularly among elderly and immunosuppressed individuals. Although most early-stage cases are cured with surgery, a relevant minority present with high-risk features or anatomically complex disease. Immune checkpoint inhibitors (ICIs) have transformed the management of advanced CSCC and are increasingly being evaluated in perioperative settings. This review critically examines current evidence for adjuvant and neoadjuvant immunotherapy in resectable CSCC. Neoadjuvant ICIs studies, including cemiplimab, pembrolizumab, and nivolumab±ipilimumab, have reported consistent and striking rates of major and complete pathologic responses, frequently exceeding 50% and accompanied by opportunities for surgical or radiotherapy de-escalation. In contrast, adjuvant anti-PD-1 trials have produced divergent results: KEYNOTE-630 was negative, while C-POST improved disease-free, but not overall survival. These discrepancies highlight persistent limitations in risk stratification, since commonly used staging systems (American Joint Committee on Cancer, Brigham and Women’s Hospital, Salamanca) insufficiently reflect disease biology and fail to incorporate immunosuppression, functional outcomes, or extent of planned surgery. Furthermore, the generalizability of current evidence is constrained by the exclusion of immunosuppressed populations and by rigid trial protocols that often mandate multimodal treatment, irrespective of biological sensitivity. Such ‘one-size-fits-all’ approaches miss critical opportunities for organ preservation and de-escalation. The future of early CSCC management lies in response-adapted strategies to tailor the extent of surgery, radiation, and systemic therapy. Next-generation studies must embrace biomarker-driven designs and broader inclusion criteria, approaching CSCC as a unique biological entity that demands a precision-medicine framework.
Boutros et al. (Fri,) studied this question.